Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Hexatronic in conjunction with the acquisition of Opternus GmbH
Mandate

Vinge advises Hexatronic in conjunction with the acquisition of Opternus GmbH

October 25, 2018 M&A

Vinge has advised Hexatronic Group AB (publ), listed on Nasdaq Stockholm mid‑cap, in connection with the acquisition of the entire share capital in the German fibre optic company Opternus GmbH.

Opternus is the market leader within sales and service of fibre welds and measurement equipment on the fast growing German market for fibre optic equipment. The purchase price amounts to MEUR 10 on a cash and debt free basis as well as an earnout of a maximum of MEUR 2.7. The purchase price is paid with MEUR 9 in cash and MEUR 1 as newly issued shares in Hexatronic. Closing, which is subject to customary conditions, is anticipated shortly.

Vinge’s team primarily consisted of responsible partner Anders Strid, Wibeke Sorling and corporate assistant Camilla Andersson. In addition, ALP Rechtsanwälte through Dr. Sven Oksaar acted as local counsel.
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024